List of Excipients in Branded Drug JINTELI

Generic Drugs Containing JINTELI

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0093-3122	CALCIUM STEARATE
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0093-3122	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0093-3122	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0093-3122	SODIUM STARCH GLYCOLATE TYPE A POTATO
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0093-3122	STARCH, CORN
Physicians Total Care Inc	norethindrone acetate and ethinyl estradiol	54868-6251	CALCIUM STEARATE
Physicians Total Care Inc	norethindrone acetate and ethinyl estradiol	54868-6251	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in JINTELI?

# Of NDCs	Excipient
2	CALCIUM STEARATE
2	CELLULOSE, MICROCRYSTALLINE
2	LACTOSE MONOHYDRATE
2	SODIUM STARCH GLYCOLATE TYPE A POTATO
2	STARCH, CORN

Jinteli Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Jinteli is a low-dose oral hormone replacement product containing norethindrone acetate 1 mg and ethinyl estradiol 5 mcg. Its commercial opportunity is driven less by active-ingredient exclusivity and more by reliable supply, dose uniformity, patient tolerability, differentiated packaging, and efficient regulatory execution. The product’s mature active ingredients create a low barrier to generic substitution, but they also support private-label, authorized-generic, contract-manufacturing, and reformulation opportunities.

What is Jinteli and how is it regulated?

Jinteli is a prescription tablet used for the treatment of moderate-to-severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause. The product contains:

Attribute	Jinteli
Active ingredients	Norethindrone acetate 1 mg; ethinyl estradiol 5 mcg
Dosage form	Oral tablet
Therapeutic category	Menopausal hormone therapy
Route	Oral
Regulatory status	FDA-approved prescription drug
Product type	Estrogen-progestin combination
Primary commercial risks	Generic substitution, supply reliability, safety perception, limited differentiation

Jinteli is subject to the FDA framework governing prescription drug labeling, manufacturing, postapproval changes, and therapeutic equivalence. The product is not a biologic, so biosimilar pathways do not apply. Competition would arise through generic or therapeutically equivalent oral products rather than biosimilars.

The low ethinyl estradiol dose and fixed norethindrone acetate combination position Jinteli in a mature menopausal hormone therapy segment. The label carries class warnings associated with estrogen and estrogen-progestin therapy, including cardiovascular, thromboembolic, dementia, and malignancy risks described in FDA-approved labeling.[1]

What excipients are used in Jinteli tablets?

Current product labeling identifies conventional tablet excipients used for direct compression or wet-granulation performance, tablet integrity, lubrication, and film coating. The formulation is generally understood to contain lactose-based filler, starch or pregelatinized starch, a disintegrant, povidone or another binder, magnesium stearate, and conventional coating materials.

The relevant excipient functions are:

Excipient function	Typical formulation role	Commercial relevance
Diluent	Provides tablet mass for a 5 mcg ethinyl estradiol dose	Critical for content uniformity
Binder	Improves granule and tablet cohesion	Controls friability and compression behavior
Disintegrant	Promotes tablet breakup after ingestion	Affects dissolution and bioavailability
Lubricant	Prevents sticking and improves ejection	Excess can slow dissolution
Film former	Protects the tablet and improves appearance	Supports identification and stability
Opacifier or pigment	Controls color and light protection	Helps distinguish strengths and products
Glidant	Improves powder flow	Supports high-speed tableting

The active ingredients are present at different concentration scales. Norethindrone acetate is present at milligram strength, while ethinyl estradiol is present at microgram strength. That imbalance makes content uniformity a central formulation issue. Small segregation effects can materially affect the low-dose estrogen component.

A commercial developer should rely on the current FDA labeling and approved chemistry, manufacturing, and controls information before treating any excipient list as definitive. Public labeling can identify inactive ingredients, but it does not disclose the full quantitative composition, manufacturing process, granulation endpoint, blend order, or critical process parameters.[1,2]

How does the Jinteli formulation affect product development?

The primary technical challenge is uniform distribution of ethinyl estradiol throughout the tablet blend. The formulation strategy should address four issues:

1. Low-dose active distribution
2. Blend segregation
3. Dissolution reproducibility
4. Stability of the hormone combination

A robust development program would evaluate premixing or geometric dilution of ethinyl estradiol with a selected carrier before full-batch blending. The carrier should have predictable particle-size distribution and low segregation risk. Direct blending may be commercially attractive, but it requires strong controls over particle size, density, electrostatic behavior, and mixing time.

Wet granulation can improve content uniformity and reduce segregation, but it increases process complexity and may introduce moisture-related stability concerns. Dry granulation may provide a compromise for manufacturers seeking improved flow and density without substantial water exposure.

Excipient selection should be linked to dissolution and stability data rather than treated as a simple substitution exercise. Changes in lubricant concentration, disintegrant grade, coating weight, or granulation method can affect release behavior even when the active ingredients and nominal strengths remain unchanged.

What formulation opportunities exist for Jinteli?

Lactose-free Jinteli formulations

A lactose-free formulation is a practical differentiation opportunity. Many oral tablets use lactose as a diluent, but lactose avoidance can address patients with intolerance, excipient preferences, or pharmacy-level substitution requirements.

Potential replacement diluents include microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected starch-based systems. Each option creates different risks:

Alternative diluent	Potential benefit	Main development risk
Microcrystalline cellulose	Strong compaction and broad supplier availability	May alter disintegration and tablet hardness
Mannitol	Good mouthfeel and low hygroscopicity	Higher cost and different compression behavior
Dibasic calcium phosphate	High density and good flow	Possible incompatibility or slower dissolution
Starch-based diluent	Familiar processing profile	Moisture sensitivity and variable flow

A lactose-free product would need comparative dissolution, stability, impurity, and bioequivalence support. If the formulation is materially different, the sponsor may need a more extensive regulatory package than a narrowly controlled generic formulation change.

Dye-free and low-allergen formulations

A dye-free tablet can appeal to patients and institutions seeking simpler inactive-ingredient profiles. The commercial value is likely higher in specialty pharmacy, direct-to-consumer channels, and health-system contracting than in traditional retail pharmacy, where therapeutic equivalence and price remain dominant.

Potential positioning claims must remain consistent with FDA labeling and advertising requirements. The absence of a particular dye or allergen should be supported by verified composition and controlled supplier documentation.

Improved low-dose content uniformity

The strongest technical opportunity is a formulation that improves dose uniformity and reduces batch rejection risk. The commercial benefit may include:

• Lower manufacturing loss
• Fewer out-of-specification investigations
• Better process capability
• More reliable supply
• Lower cost of quality
• Improved regulatory confidence for additional manufacturing sites

A developer could seek protection for a narrow process or composition defined by blend uniformity, particle-size distribution, granulation parameters, or dissolution performance. Such claims may be more defensible than broad claims covering the known active ingredients.

Stability-oriented formulations

Ethinyl estradiol and norethindrone acetate require protection from conditions that can promote degradation. Commercial development may focus on:

• Low-moisture excipient systems
• High-barrier blister packaging
• Light-protective coatings
• Desiccant-supported bottles
• Reduced oxygen exposure
• Improved impurity control during long-term storage

Packaging can produce a meaningful product advantage where the underlying tablet is difficult to differentiate. A blister pack may support unit-dose adherence and better moisture protection, while a bottle may offer lower packaging cost and easier dispensing.

What patents protect Jinteli and when does Jinteli lose exclusivity?

Jinteli contains long-established active ingredients, and broad composition-of-matter patent protection for norethindrone acetate and ethinyl estradiol is not expected to provide a current barrier to generic development. The practical exclusivity analysis depends on the product’s FDA listing, any Orange Book patents, regulatory exclusivity, and the status of competing abbreviated new drug applications.

Exclusivity category	Jinteli relevance
Active-ingredient patent	Historical protection is expected to have expired
Combination patent	Any remaining rights would require confirmation in current FDA records
Formulation patent	Potentially relevant only if listed or separately enforceable
Method-of-use patent	May affect a particular labeled indication
Regulatory exclusivity	Must be verified against the current FDA approval record
Orange Book listing	Current listing and patent entries require direct database confirmation
Generic pathway	ANDA competition is the principal risk

A patent review should examine the FDA Orange Book, the approved Jinteli labeling, the relevant NDA history, and U.S. Patent and Trademark Office records.[2,3] Public product information alone does not establish whether a patent is currently listed, expired, delisted, or subject to a litigation settlement.

For a new excipient-based product, patentability is more likely to arise from a specific technical combination than from the presence of a conventional excipient. A claim directed broadly to “norethindrone acetate, ethinyl estradiol, and a tablet excipient” would face substantial prior-art risk. Stronger claim concepts could involve:

• A defined low-dose blend with measured uniformity
• A specified particle-size relationship
• A moisture-controlled composition
• A dissolution profile tied to a defined excipient system
• A package-composition combination that extends stability
• A manufacturing process that reduces segregation

What is the Orange Book status of Jinteli?

The Orange Book is the primary FDA source for determining whether an NDA-listed product has patents or exclusivity relevant to generic approval. A commercial diligence review should verify:

• The Jinteli NDA number and active marketing status
• Therapeutic-equivalence listings
• Patent numbers and expiration dates
• Use codes for any method-of-use patents
• Regulatory exclusivity dates
• Whether patents have been withdrawn or delisted
• Whether an ANDA applicant has filed a Paragraph IV certification

The existence of an Orange Book patent does not automatically prevent generic entry. A Paragraph IV certification can trigger patent litigation, while a Paragraph III certification typically postpones approval until patent expiration. A product with no current listed patents may still face non-Orange Book litigation involving manufacturing processes, trade secrets, trademarks, or formulation rights.

Which companies are challenging Jinteli exclusivity?

Generic companies typically challenge a mature oral combination through an ANDA rather than a 505(b)(2) application. A Paragraph IV challenger may assert that a listed patent is invalid, unenforceable, or not infringed. If the patent holder files suit within the statutory period, FDA approval can be subject to a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and court developments.[4]

The competitive field may include:

• Generic manufacturers with ANDAs for the same strength
• Contract manufacturers supplying private-label products
• Authorized-generic distributors
• Manufacturers of alternative oral estrogen-progestin combinations
• Transdermal and vaginal hormone therapy providers

The identity of active challengers, filing dates, certifications, and litigation status must be drawn from current FDA records and PACER or court docket data. Product availability alone does not prove an ANDA challenge or Paragraph IV filing.

What commercial opportunities exist for Jinteli?

Authorized generic and private-label supply

The most direct opportunity is supply of an equivalent product to wholesalers, pharmacy chains, health systems, and specialty distributors. Success depends on:

• FDA-approved manufacturing capacity
• Competitive cost of goods
• Reliable supply of both active ingredients
• Ability to manage low-dose content uniformity
• Packaging flexibility
• Adequate inventory for shortage or allocation events

A private-label strategy can use the same approved product with customer-specific labeling and packaging, subject to regulatory and contractual controls.

Reformulated product under a differentiated brand

A branded reformulation could target a specific unmet need, such as lactose avoidance, improved packaging, or a simplified excipient profile. The regulatory pathway would depend on the degree of change. A conventional generic approach would normally require ANDA eligibility, while a materially differentiated formulation may require a 505(b)(2) application supported by bridging data and, where necessary, clinical or bioequivalence studies.[5]

Manufacturing technology licensing

Excipient and process technology may be licensed to manufacturers that lack expertise in low-dose hormone blending. The most licensable assets would be:

• A validated content-uniformity process
• A scalable granulation method
• A stability-enhancing coating system
• A high-barrier packaging configuration
• A control strategy that reduces batch failures

The value of the license would depend on whether the technology reduces cost or creates regulatory differentiation. A routine excipient substitution would have limited standalone licensing value.

Geographic expansion

The active ingredients are recognized internationally, but regulatory requirements differ by jurisdiction. Opportunities may exist in markets where:

• Oral menopausal hormone therapy remains widely prescribed
• Local generic competition is limited
• Reliable combination-product supply is constrained
• Blister packaging is preferred
• A lactose-free or dye-free product has commercial relevance

A U.S. approval does not automatically establish regulatory approval in Canada, Europe, Japan, or emerging markets. Local requirements may address bioequivalence, impurity limits, excipient acceptability, labeling, pharmacovigilance, and hormonal product risk management.

How strong is the Jinteli patent estate?

The likely strength of the Jinteli patent estate is limited for broad active-ingredient or basic formulation claims because the combination and its dosage form are mature. The stronger commercial barriers are operational and regulatory:

Barrier	Likely strength
Broad active-ingredient patent	Low
Basic tablet formulation patent	Low to moderate
Narrow process patent	Moderate if technically validated
Stability and packaging patent	Moderate if data show unexpected benefit
Manufacturing know-how	Moderate to high if nonpublic and difficult to replicate
Regulatory approval and quality system	High practical importance
Supply-chain control	High during shortages or constrained supply

A patent strategy should avoid relying on conventional excipients alone. The best protection would combine narrow patent claims with trade secrets covering process parameters, supplier qualification, analytical methods, and scale-up controls.

What litigation and settlement issues affect Jinteli?

Potential litigation can involve:

• Paragraph IV patent challenges
• ANDA infringement claims
• Trademark disputes involving Jinteli branding
• Manufacturing process disputes
• Trade-secret claims
• Contract disputes with suppliers or licensees
• Product-liability litigation involving estrogen-progestin risks

Settlement agreements in Hatch-Waxman cases may specify an authorized generic launch, a license date, or restrictions on generic commercialization. Any settlement analysis must distinguish between a patent settlement, a supply agreement, and a commercial licensing arrangement. They have different effects on entry timing and competition.

No current litigation or settlement should be treated as dispositive without a live docket and FDA-record review.

How does Jinteli compare with competing menopause therapies?

Jinteli competes with other oral estrogen-progestin products and with nonoral therapies.

Product category	Competitive advantage	Limitation versus Jinteli
Oral estrogen-progestin tablet	Familiar dosing and low distribution cost	Systemic exposure and class safety concerns
Transdermal estrogen plus progestogen	Potentially different pharmacokinetic and risk profile	More complex regimen or higher cost
Vaginal estrogen	Local symptom treatment	Does not provide the same systemic therapy
Estrogen-only therapy	Simpler hormone regimen for selected patients	Not appropriate for patients with an intact uterus without endometrial protection
Nonhormonal therapy	Avoids estrogen exposure	May provide different efficacy for vasomotor symptoms

Jinteli’s commercial position depends on price, prescriber familiarity, availability, and patient acceptance. Excipient differentiation is unlikely to overcome a major price disadvantage, but it can support a premium or defend a niche channel when tied to measurable tolerability or stability benefits.

What generic launch risks exist for Jinteli?

Generic entry could reduce price and market share rapidly because the product is an oral tablet with established active ingredients. Launch risk is highest if:

• No enforceable Orange Book patent remains
• Multiple ANDAs are approved
• The product is therapeutically equivalent
• Wholesalers have sufficient inventory
• Substitution is permitted under state pharmacy law
• The brand has limited prescriber loyalty

A staged launch scenario is possible:

Scenario	Commercial effect
First generic enters with limited competition	Significant price pressure, but first-mover share opportunity
Several generics launch together	Rapid erosion and lower margins
Supply disruption affects competitors	Temporary opportunity for reliable manufacturers
Differentiated reformulation launches	Niche protection rather than full market defense
Authorized generic launches	Greater control over channel pricing and supply

Key Takeaways

• Jinteli is a mature oral hormone replacement tablet containing norethindrone acetate 1 mg and ethinyl estradiol 5 mcg.
• The main formulation challenge is uniform distribution of microgram-level ethinyl estradiol.
• Excipient opportunities include lactose-free, dye-free, low-moisture, stability-oriented, and improved-content-uniformity formulations.
• Broad active-ingredient patent protection is unlikely to be the main barrier to competition.
• Narrow process, composition, packaging, and stability claims offer the strongest potential intellectual-property positions.
• Authorized-generic, private-label, contract-manufacturing, and supply-reliability strategies are commercially more realistic than broad premium pricing.
• Jinteli is not subject to biosimilar competition. The relevant competitive pathway is generic substitution through ANDAs.
• Current Orange Book patents, Paragraph IV certifications, litigation, settlements, and regulatory exclusivity must be verified against live FDA and court records before investment or licensing decisions.

FAQs

Can a lactose-free Jinteli product receive separate patent protection?

Possibly, but a broad claim covering replacement of lactose with another conventional diluent would face prior-art and obviousness challenges. Patent value would improve if the formulation produced a demonstrated technical benefit, such as superior content uniformity, dissolution, stability, or reduced impurity formation.

Would an excipient change require a new FDA application?

The pathway depends on the nature of the change and the applicant’s regulatory position. A generic manufacturer may use an ANDA if the product remains eligible and meets the applicable sameness and bioequivalence requirements. A materially differentiated branded product may require a 505(b)(2) application.

Is Jinteli eligible for biosimilar competition?

No. Jinteli is a small-molecule oral tablet, not a biologic. Competition would come through generic drug applications, authorized generics, private-label products, and alternative hormone therapy products.

Can packaging create a defensible Jinteli commercial product?

Yes. High-barrier blister packaging, unit-dose adherence packaging, and stability-enhancing configurations can create commercial differentiation. Patent protection would require evidence that the packaging produces a non-obvious technical or stability advantage.

What is the most attractive licensing asset around Jinteli?

A validated low-dose manufacturing platform is likely more valuable than a routine excipient recipe. A process that improves ethinyl estradiol uniformity, reduces batch failures, supports scale-up, or extends shelf life can provide measurable value to generic and contract manufacturers.

References

1. U.S. Food and Drug Administration. (n.d.). Jinteli: Norethindrone acetate and ethinyl estradiol tablets, prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Patent and Trademark Office. (n.d.). Patent Center.
4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications.
5. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA guidance.